Incidence and correlates of hiv-1 rna detection in the breast milk of women receiving haart for the prevention of hiv-1 transmission

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Slyker, Jennifer A ^a   Chung, Michael H ^a   Lehman, Dara A ^c   Kiarie, James ^d   Kinuthia, John ^b   Holte, Sarah ^a   Tapia, Kenneth ^a   Njiri, Francis ^d   Overbaugh, Julie ^c   John Stewart, Grace ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b KENYATTA NATIONAL HOSPITAL   (Kenya)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; NEVIRAPINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST DISEASE; BREAST MILK; CD4 LYMPHOCYTE COUNT; CELL FREE SYSTEM; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MATERNAL TREATMENT; MORBIDITY; NONHUMAN; PRIMIPARA; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT DURATION; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; BLOOD; CYTOLOGY; DISEASE TRANSMISSION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; ISOLATION AND PURIFICATION; KENYA; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KENYA; MILK, HUMAN; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 84855708230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029777     Document Type: Article

References (28)

1. Rousseau CM, Nduati RW, Richardson BA, John-Stewart GC, Mbori-Ngacha DA, et al. (2004) Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis 190: 1880-1888.
2. Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, et al. (2003) Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 187: 741-747.
3. Semba RD, Kumwenda N, Hoover DR, Taha TE, Quinn TC, et al. (1999) Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 180: 93-98.
4. Lehman DA, Chung MH, John-Stewart GC, Richardson BA, Kiarie J, et al. (2008) HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS 22: 1475-1485.
5. Koulinska IN, Villamor E, Chaplin B, Msamanga G, Fawzi W, et al. (2006) Transmission of cell-free and cell-associated HIV-1 through breast-feeding. J Acquir Immune Defic Syndr 41: 93-99.
6. Shapiro RL, Ndung'u T, Lockman S, Smeaton LM, Thior I, et al. (2005) Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 192: 713-719.
7. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, et al. (2008) Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial. Antivir Ther 13: 799-807.
8. Sklar PA, Ward DJ, Baker RK, Wood KC, Gafoor Z, et al. (2002) Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 16: 2035-2041.
9. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, et al. (2005) Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 293: 817-829.
10. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, et al. (2005) Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 41: 1326-1332.
11. Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, et al. (2001) Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 286: 171-179.
12. Macias J, Palomares JC, Mira JA, Torres MJ, Garcia-Garcia JA, et al. (2005) Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect 51: 195-200.
13. Jones LE, Perelson AS, (2007) Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 45: 483-493.
14. Phiri W, Kasonka L, Collin S, Makasa M, Sinkala M, et al. (2006) Factors influencing breast milk HIV RNA viral load among Zambian women. AIDS Res Hum Retroviruses 22: 607-614.
15. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, et al. (2009) Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 52: 406-416.
16. Chama CM, Bello M, Ajayi BA, Zarma S, Gashau W, (2010) The use of highly active antiretroviral therapy for the prevention of mother-to-child transmission of the human immunodeficiency virus in Nigeria. J Obstet Gynaecol 30: 362-366.
17. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, et al. (2010) Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362: 2282-2294.
18. DeVange Panteleeff D, John G, Nduati RW, Mbori-Ngacha DA, Richardson BA, et al. (1999) Rapid method for screening dried blood samples on filter paper for HIV type 1 DNA. J Clin Microbiol 37: 350-353.
19. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, et al. (2000) Evaluation of performance of the Gen-Probe HIV type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clinical Microbiol 38: 2688-2695.
20. Benki S, McClelland RS, Emery S, Baeten JM, Richardson BA, et al. (2006) Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J Clin Microbiol 44: 4357-4362.
21. de Vincenzi I, (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11: 171-180.
22. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, et al. (2010) Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 362: 2271-2281.
23. Salazar-Gonzalez JF, Salazar MG, Learn GH, Fouda GG, Kang HH, et al. (2011) Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol 85: 2751-2763.
24. Gray RR, Salemi M, Lowe A, Nakamura KJ, Decker WD, et al. (2011) Multiple independent lineages of HIV-1 persist in breast milk and plasma. AIDS 25: 143-152.
25. World Health Organization (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access Geneva.
26. Giuliano M, Guidotti G, Andreotti M, Pirillo MF, Villani P, et al. (2007) Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program. J Acquir Immune Defic Syndr 44: 286-291.
27. Patel D, Cortina-Borja M, Thorne C, Newell ML, (2007) Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 44: 1647-1656.
28. Weinberg A, Harwood JE, McFarland EJ, Pappas J, Davies J, et al. (2009) Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol 2009: 621780.